Showing results (181-190 of 221) with videos related to

Sort By:
Pageof 23
Hepatology Communications|November 9, 2020
ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data ValidationDaniel Q Huang, Yee Hui Yeo, Eunice Tan, et al.
Alimentary Pharmacology & Therapeutics|January 30, 2023
The prognostic value of including non-alcoholic fatty liver disease in the definition of metabolic syndromeClarissa Elysia Fu, Jie Ning Yong, Cheng Han Ng, et al.
Alimentary Pharmacology & Therapeutics|November 7, 2020
Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg)Seng Gee Lim, Wah Wah Phyo, Joanna Zhi Jie Ling, et al.
Antiviral Research|April 19, 2024
Quantitative HBeAg is a strong predictor of HBeAg loss among patients receiving pegylated interferonDaniel Q Huang, Liang Shen, Wah Wah Phyo, et al.
Circulation|December 26, 2024
Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi ApproachNicholas W S Chew, Anurag Mehta, Rachel Sze Jen Goh, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 2, 2025
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical PracticeLuis Antonio Diaz, Veeral Ajmera, Juan Pablo Arab, et al.
Metabolism: Clinical and Experimental|November 29, 2023
Rising global burden of cancer attributable to high BMI from 2010 to 2019Darren Jun Hao Tan, Cheng Han Ng, Mark Muthiah, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 26, 2024
Prevalence of Chronic Liver Disease in Cholangiocarcinoma: A Meta-AnalysisEthan Kai Jun Tham, Ryan Yanzhe Lim, Benjamin Koh, et al.
Hepatology (Baltimore, Md.)|March 11, 2021
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine PracticeHidenori Toyoda, Jennifer Leong, Charles Landis, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 10, 2024
Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular CarcinomaRebecca Wenling Zeng, Christen En Ya Ong, Elden Yen Hng Ong, et al.
Pageof 23